1
|
Redig AJ and McAllister SS: Breast cancer
as a systemic disease: A view of metastasis. J Intern Med.
274:113–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
2
|
Sharma P: Biology and management of
patients with triple-negative breast cancer. Oncologist.
21:1050–1062. 2016. View Article : Google Scholar : PubMed/NCBI
|
3
|
Ho AY, Gupta G, King TA, Perez CA, Patil
SM, Rogers KH, Wen YH, Brogi E, Morrow M, Hudis CA, et al:
Favorable prognosis in patients with T1a/T1bN0 triple-negative
breast cancers treated with multimodality therapy. Cancer.
118:4944–4952. 2012. View Article : Google Scholar : PubMed/NCBI
|
4
|
Shen M, Jiang YZ, Wei Y, Ell B, Sheng X,
Esposito M, Kang J, Hang X, Zheng H, Rowicki M, et al: Tinagl1
suppresses triple-negative breast cancer progression and metastasis
by simultaneously inhibiting integrin/FAK and EGFR signaling.
Cancer Cell. 35:64–80.e7. 2019. View Article : Google Scholar : PubMed/NCBI
|
5
|
Chen Y, Yang Y, Wang F, Wan K, Yamane K,
Zhang Y and Lei M: Crystal structure of human histone
lysine-specific demethylase 1 (LSD1). Proc Natl Acad Sci USA.
103:13956–13961. 2006. View Article : Google Scholar : PubMed/NCBI
|
6
|
Serce N, Gnatzy A, Steiner S, Lorenzen H,
Kirfel J and Buettner R: Elevated expression of LSD1
(Lysine-specific demethylase 1) during tumour progression from
pre-invasive to invasive ductal carcinoma of the breast. BMC Clin
Pathol. 12:132012. View Article : Google Scholar : PubMed/NCBI
|
7
|
Ketscher A, Jilg CA, Willmann D, Hummel B,
Imhof A, Rüsseler V, Hölz S, Metzger E, Müller JM and Schüle R:
LSD1 controls metastasis of androgen-independent prostate cancer
cells through PXN and LPAR6. Oncogenesis. 3:e1202014. View Article : Google Scholar : PubMed/NCBI
|
8
|
Hayami S, Kelly JD, Cho HS, Yoshimatsu M,
Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, et al:
Overexpression of LSD1 contributes to human carcinogenesis through
chromatin regulation in various cancers. Int J Cancer. 128:574–586.
2011. View Article : Google Scholar : PubMed/NCBI
|
9
|
Ding J, Zhang ZM, Xia Y, Liao GQ, Pan Y,
Liu S, Zhang Y and Yan ZS: LSD1-mediated epigenetic modification
contributes to proliferation and metastasis of colon cancer. Br J
Cancer. 109:994–1003. 2013. View Article : Google Scholar : PubMed/NCBI
|
10
|
Amente S, Milazzo G, Sorrentino MC,
Ambrosio S, Di Palo G, Lania L, Perini G and Majello B:
Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively
repress tumor suppressor genes in neuroblastoma. Oncotarget.
6:14572–14583. 2015. View Article : Google Scholar : PubMed/NCBI
|
11
|
Shao G, Wang J, Li Y, Liu X, Xie X, Wan X,
Yan M, Jin J, Lin Q, Zhu H, et al: Lysine-specific demethylase 1
mediates epidermal growth factor signaling to promote cell
migration in ovarian cancer cells. Sci Rep. 5:153442015. View Article : Google Scholar : PubMed/NCBI
|
12
|
Lim S, Janzer A, Becker A, Zimmer A,
Schüle R, Buettner R and Kirfel J: Lysine-specific demethylase 1
(LSD1) is highly expressed in ER-negative breast cancers and a
biomarker predicting aggressive biology. Carcinogenesis.
31:512–520. 2010. View Article : Google Scholar : PubMed/NCBI
|
13
|
Cao C, Vasilatos SN, Bhargava R, Fine JL,
Oesterreich S, Davidson NE and Huang Y: Functional interaction of
histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1
(LSD1) promotes breast cancer progression. Oncogene. 36:133–145.
2017. View Article : Google Scholar : PubMed/NCBI
|
14
|
Qin Y, Vasilatos SN, Chen L, Wu H, Cao Z,
Fu Y, Huang M, Vlad AM, Lu B, Oesterreich S, et al: Inhibition of
histone lysine-specific demethylase 1 elicits breast tumor immunity
and enhances antitumor efficacy of immune checkpoint blockade.
Oncogene. 38:390–405. 2019. View Article : Google Scholar : PubMed/NCBI
|
15
|
Forneris F, Battaglioli E, Mattevi A and
Binda C: New roles of flavoproteins in molecular cell biology:
Histone demethylase LSD1 and chromatin. FEBS J. 276:4304–4312.
2009. View Article : Google Scholar : PubMed/NCBI
|
16
|
Scoumanne A and Chen X: The
lysine-specific demethylase 1 is required for cell proliferation in
both p53-dependent and -independent manners. J Biol Chem.
282:15471–15475. 2007. View Article : Google Scholar : PubMed/NCBI
|
17
|
Nagasawa S, Sedukhina AS, Nakagawa Y,
Maeda I, Kubota M, Ohnuma S, Tsugawa K, Ohta T, Roche-Molina M,
Bernal JA, et al: LSD1 overexpression is associated with poor
prognosis in basal-like breast cancer, and sensitivity to PARP
inhibition. PLoS One. 10:e01180022015. View Article : Google Scholar : PubMed/NCBI
|
18
|
Boulding T, McCuaig RD, Tan A, Hardy K, Wu
F, Dunn J, Kalimutho M, Sutton CR, Forwood JK, Bert AG, et al: LSD1
activation promotes inducible EMT programs and modulates the tumour
microenvironment in breast cancer. Sci Rep. 8:732018. View Article : Google Scholar : PubMed/NCBI
|
19
|
Li L, Liu X, He L, Yang J, Pei F, Li W,
Liu S, Chen Z, Xie G, Xu B, et al: ZNF516 suppresses EGFR by
targeting the CtBP/LSD1/CoREST complex to chromatin. Nat Commun.
8:6912017. View Article : Google Scholar : PubMed/NCBI
|
20
|
Hu X, Xiang D, Xie Y, Tao L, Zhang Y, Jin
Y, Pinello L, Wan Y, Yuan GC and Li Z: LSD1 suppresses invasion,
migration and metastasis of luminal breast cancer cells via
activation of GATA3 and repression of TRIM37 expression. Oncogene.
38:7017–7034. 2019. View Article : Google Scholar : PubMed/NCBI
|
21
|
Sehrawat A, Gao L, Wang Y, Bankhead A III,
McWeeney SK, King CJ, Schwartzman J, Urrutia J, Bisson WH, Coleman
DJ, et al: LSD1 activates a lethal prostate cancer gene network
independently of its demethylase function. Proc Natl Acad Sci USA.
115:E4179–E4188. 2018. View Article : Google Scholar : PubMed/NCBI
|
22
|
Wang M, Liu X, Guo J, Weng X, Jiang G,
Wang Z and He L: Inhibition of LSD1 by Pargyline inhibited process
of EMT and delayed progression of prostate cancer in vivo. Biochem
Biophys Res Commun. 467:310–315. 2015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Xu J, Sun J, Wang P, Ma X and Li S:
Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug
micellar carrier for anticancer drugs. J Drug Target. 26:448–457.
2018. View Article : Google Scholar : PubMed/NCBI
|